The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Understanding LRRK2 Biology, 2010Biochemical characterization of full length human recombinant LRRK1 and LRRK2
Promising Outcomes of Original Grant:
In our initial application we proposed to take advantage of a lentiviral system recently developed in KULeuven to express full-length, soluble human LRRK1 and... -
Research Grant, 2010Longitudinal Follow-Up of Clinical and Neuroimaging Signs and Biomarkers in Symptoms & Side Effects and aSymptoms & Side Effects LRRK2 Mutation Carriers in Comparison to Idiopathic PD and Controls
Objective/Rationale:
Parkinson’s disease (PD) is a common neurodegenerative disease that leads to progressive motor impairment as well as autonomic and cognitive disturbances. The cause of most of... -
MJFF Research Grant, 2010LRRK2 G2019S Disease Penetrance Modifiers
Objective/Rationale:
The most commonly found mutation in Parkinson’s disease patients is LRRK2 G2019S. This mutation can lead to the development of Parkinson’s disease at very different ages, from... -
MJFF Research Grant, 2010Characterization of an Inhibitor Compound of LRRK2 Function
Objective/Rationale:
LRRK2 (Leucine-Rich Repeat Kinase 2) is a protein thought to be involved in regulating signaling pathways in cells. Mutations in the gene for LRRK2 are associated with some... -
Research Grant, 2010Symptoms and Side Effects of LRRK2 Mutation Carriers and Assessment of Factors Influencing LRRK2-related PD Expression
Objective/Rationale:
By incorporating our Spanish LRRK2 cohort with G2019S and R1441G mutations into the existing LRRK2 Cohort Consortium (L2CC) of people of Ashkenazi Jewish and North African Arab... -
MJFF Research Grant, 2010Development of Selective LRRK2 Inhibitors
Objective/Rationale:
LRRK2 kinase has been implicated as a potential therapeutic target for the treatment of Parkinson’s disease. The goal of our project is to make experimental drugs to test whether...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.